The Bone Marrow Transplant Survivor Study is a retrospective cohort study in which participants who received hematopoietic cell transplantation (HCT) between 1974 and 1998 and survived for X2 years completed a 255-item questionnaire on late effects occurring after HCT. There were 281 survivors with acute myeloid leukemia (AML) and 120 with acute lymphoblastic leukemia (ALL). Siblings of participants (n ¼ 319) were recruited for comparison. Median age at interview was 36.5 years for survivors and 44 years for siblings. Median follow-up after HCT was 8.4 years. Conditioning included total body irradiation in 86% of AML and 100% of ALL subjects. The frequencies of late effects did not differ between ALL and AML survivors. Compared with siblings, survivors had a higher frequency of diabetes, hypothyroidism, osteoporosis, exercise-induced shortness of breath, neurosensory impairments and problems with balance, tremor or weakness. In multivariable analysis, the risk of these outcomes did not differ by diagnosis. Survivors after allogeneic HCT had higher odds of diabetes (odds ratio (OR) ¼ 3.9, P ¼ 0.04), osteoporosis (OR ¼ 3.1, P ¼ 0.05), abnormal sense of touch (OR ¼ 2.6, P ¼ 0.02) and reported their overall health as fair or poor (OR ¼ 2.2, P ¼ 0.03). Ongoing surveillance for these late effects and appropriate interventions are required to improve the health status of ALL and AML survivors after HCT.
Introduction
Acute leukemias (ALs: including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)) are the most common indication for allogeneic hematopoietic cell transplantation (HCT) worldwide accounting for nearly 10 000 transplants reported worldwide to the Center for International Blood and Marrow Transplant Research in 2006. 1 HCT is routinely offered to patients with AL in second complete remission (CR), as well as to high-risk patients in first CR. Overall survival for patients who received matched-related HCT in first CR is reported to be 50-60%. 2, 3 Donor type (related vs unrelated) does not seem to impact survival for patients receiving HCT in first CR. 4 Survival rates are lower after HCT in second CR, approaching 40%. Despite the fact that ALs account for the largest group of survivors after HCT, there have been few studies that have focused on the unique long-term outcomes and late effects that these patients may face. The impact of HCT on organ function, functional performance and quality of life can be significant. We have previously investigated these outcomes in a population of patients who had undergone HCT for chronic myeloid leukemia and found that compared with age-and gender-matched siblings, chronic myeloid leukemia survivors were more likely to develop ocular, oral, endocrine, gastrointestinal, musculoskeletal and neurological impairments. 5 Presence of chronic graft-vs-host disease (cGvHD) was the most important predictor of adverse medical late effects, and also of poor overall health among chronic myeloid leukemia survivors. On the other hand, patients who had undergone autologous HCT for lymphoma, reported a higher frequency of cataracts, dry mouth, hypothyroidism, osteoporosis, congestive heart failure, exercise-induced shortness of breath (EISB) and neurosensory impairments as compared with the sibling comparison group. 6 These, and other issues that plague long-term survivors including the occurrence of new cancers [7] [8] [9] [10] can increase the risk of premature death from nonrelapse causes, 11, 12 and have been understudied in AL survivors. It is important to determine the burden of long-term morbidity after HCT for AL, so that patients may be appropriately counseled before HCT, and also so that targeted surveillance can be instituted for survivors.
Subjects and methods

Participants
Eligible participants included individuals who received HCT at City of Hope or University of Minnesota between 1974 and 1998 for AL, survived at least 2 years after transplantation, were alive at study participation; and had completed the questionnaire in English. The Human Subjects Committee at the participating institutions approved the protocol; informed consent was provided according to the Declaration of Helsinki Principles. Comparison with a noncancer population was made possible by asking participating survivors to invite a nearest-age sibling to the study. A total of 319 siblings participated in this study.
Data collection Clinical characteristics. Information regarding primary diagnosis, preparative regimens, stem-cell source (autologous, sibling or unrelated donor), graft type (bone marrow or peripheral blood stem cells), risk of relapse at HCT (standard or high risk) and prophylaxis and management of graft-vs-host disease (GvHD), was obtained from institutional databases.
Patients transplanted in first or second CR were considered at standard risk for relapse; all others were considered at high risk.
Adverse events. HCT survivors and siblings completed a 255-item Bone Marrow Transplant Survivor Study questionnaire, which covers the following general areas: questions regarding physical health conditions (endocrinopathies, central nervous system compromise, cardiopulmonary dysfunction, gastrointestinal and hepatic sequelae, musculoskeletal abnormalities and subsequent malignancies) diagnosed by a healthcare provider, along with age at diagnosis; presence and severity of chronic GvHD; activity limitations that interfered with daily function; access to and use of medical care; and sociodemographic characteristics (race/ethnicity, education, marital status, employment, household income and insurance). The reliability and validity of the Bone Marrow Transplant Survivor Study questionnaire has been tested, and the responses have demonstrated a high level of sensitivity and specificity, confirming that survivors are able to report the occurrence of adverse medical conditions with accuracy. 13 
Data analysis
Descriptive statistics, including means, s.d.'s, medians, ranges, frequencies and percentages were calculated for demographic and treatment factors among HCT survivors, overall and stratified by diagnosis and for the sibling comparison group. Demographic information was compared between survivors and the sibling comparison group with two sample t-tests and w 2 -statistics. The frequencies of yes responses to the questions regarding organ-system impairments, activity limitations and health status were tabulated, again overall, stratified by diagnosis, and for the sibling comparison group. Proportions were compared with these outcomes between survivors and siblings with generalized estimating equations to allow for correlations between siblings and survivors in the same families. Models were adjusted for age and gender. To estimate the total burden of disease, the number of organ system-impairments was summed for each participant and compared between survivors and siblings with a Wilcoxon's rank-sum test. The associations between diagnosis and treatment and organ-system impairments and activity limitations were evaluated in multivariate logistic regression models, adjusting for age at transplant, age at interview and gender. Results are reported as odds ratios (OR) with 95% confidence intervals (CIs) both for the overall HCT cohort and separately for those who received an allogeneic transplant. The presence of cGvHD was included in the predictive models for those who had an allogeneic transplant. SAS version 9.1 (Cary, NC, USA) was used for all analyses.
Results
Study participants
Of the 673 eligible HCT survivors, 584 (87%) were successfully contacted and 401 (69%) participated. Participants were more likely to be women (46.5 vs 35.7%, Po0.001), older at HCT (26.3±14.4 vs 20.4±13.6 years, Po0.001) and at study participation (35.9 ± 14.2 vs 31.7 ± 13.5 years, Po0.001), when compared with nonparticipants. Finally, when compared with nonparticipants, there was an overrepresentation of AML survivors among participants (70.1 vs 57.4%, Po0.001). Participants did not differ from nonparticipants by race/ ethnicity, time as transplantation, treating institution, stem-cell source or myeloablative regimen.
The clinical and demographic characteristics of the HCT survivors and their siblings are summarized in Table 1 . When compared with the siblings, there was an overrepresentation of men and non-whites among the HCT survivors. Furthermore, HCT survivors were younger (median age at study participation: 36.5 years, when compared with the siblings were (median age: 44 years). AML was the predominant diagnosis group in this cohort of HCT survivors (70%). Although over half of the AML survivors were women, two-thirds of the ALL survivors were men. In total, 60% of the survivors had a sibling donor and 83% had bone marrow as their primary donor source. The vast majority of HCT survivors (ALL: 100%. AML: 86%) received total body irradiation (TBI) as part of their conditioning regimen. The median length of follow-up was 8.4 (range 2.0-24.6) years. cGvHD was reported by 47% of AML survivors and 39% of ALL survivors in this cohort.
Comparison between HCT survivors and siblings
Organ system impairment. The age-and gender-adjusted comparison of the prevalence of organ-system impairment among HCT survivors and siblings is summarized in Table 2 . The comparison is presented between siblings and all AL survivors as well as between siblings and ALL or AML survivors.
Overall, the prevalence of organ-system impairments was higher among HCT survivors when compared with the siblings in nearly all systems examined.
Ocular impairment: Ocular impairments including cataracts, glaucoma and dry eyes were reported by 44.6% of HCT survivors and 11.3% of siblings (Po0.001). The most common ocular impairment among survivors was cataracts (36.4%).
Oral health: Oral health problems, including dry mouth, swollen or bleeding gums, and problems chewing or swallowing were reported by 22.4% of the HCT survivors, and 12.9% of siblings (P ¼ 0.002). The most common oral health problem reported by the study participants was swollen and bleeding gums.
Endocrine: Endocrine dysfunction under consideration included thyroid disorders and diabetes, and were significantly more common in HCT survivors (29.4%), compared with siblings (11.3%, Po0.001). Hypothyroidism was the most common condition, reported by 23.2% of HCT survivors. Diabetes was reported significantly more commonly by HCT survivors (9%) compared with 3.1% of siblings (Po0.001).
Bone health: Osteoporosis and avascular necrosis were the two most commonly reported bone health issues, and were reported more frequently by HCT survivors compared with siblings (13.2 vs 2.5%, Po0.001).
Cardiopulmonary compromise: Cardiopulmonary complications included coronary artery disease, congestive heart failure, arrhythmia, hypertension, valvular disorders, pericarditis, pulmonary fibrosis, blood clots and EISB. The prevalence of cardiopulmonary compromise was comparable between HCT survivors and siblings, with the exception of EISB, which was more common in survivors with a previous diagnosis of ALL (13.3%) than in either siblings (2.5%) or in HCT survivors with a previous diagnosis of AML (6.0%).
Gastrointestinal complications: Gastrointestinal problems included gallstones, hepatitis, cirrhosis and esophageal strictures, and were reported by 16% of HCT survivors and 9% of siblings (P ¼ 0.002). Gallstones and hepatitis were the most frequently reported conditions.
Neurological impairment: Neurosensory and neuromotor impairments were reported more frequently by HCT survivors than the siblings. Abnormal sense of taste, smell, or touch as well as problems with balance, tremor or weakness constituted the most commonly reported neurological concerns.
Total number of organ system impairments: In total, 34% of survivors and 42.9% of siblings reported no chronic conditions. Over one-third (38.2%) of HCT survivors reported impairments in more than one and 24% in more than two organ systems. Conversely, only 24.1% of siblings reported impairments in more than one and 8.7% in more than two organ systems (Po0.001). The most frequent combination of multiple system involvement for both HCT survivors and siblings was oral health problems and cardiopulmonary compromise (2.0 and 2.5%, respectively).
Functional status. Limitations in functional status were assessed in the following domains: assistance with activities of daily living such as grooming, bathing or dressing, and assistance with routine activities like housework or shopping. Study participants were also asked whether health prevented work or school attendance. Finally, participants were asked to rate their health into one of the following categories: poor, fair, good, very good and excellent. The majority of survivors did not report any limitations in functional status, however, for those who did, they were more likely than siblings to report the need for assistance with activities of daily living (3 vs 0.3%, P ¼ 0.01) as well as the need for assistance with routine activities (7.7 vs 2.5%, P ¼ 0.004, Table 3 ). Health problems interfered with school or work attendance in nearly 14% or survivors, but in only 2% of siblings (Po0.001). The majority of siblings and 82.9% of survivors rated their general health as good, very good or excellent, although HCT survivors were more likely than siblings to report their heath as fair or poor (16.7 vs 5.3%, Po0.001).
HCT survivors: clinical and demographic predictors of organ system and functional status compromise
The results of the multivariate models evaluating the associations between demographic, clinical factors and select organsystem impairments or functional status compromise are shown in Tables 4-6. Table 4 includes outcomes for all survivors, whereas Table 5 is limited to those who received an allogeneic HCT. Table 6 provides data on functional status outcomes for all HCT recipients as well as that restricted to allogeneic HCT Table 1 Clinical and demographic characteristics of the study population Prevalence of functional status limitations among survivors, overall and by diagnosis, compared with siblings Health prevents school or work attendance. Among allogeneic HCT recipients, those with cGvHD were 2.9-fold more likely to report poor health impacting school or work attendance (OR ¼ 2.93, 95% CI 1.3-6.4, P ¼ 0.008).
Self-reported poor/fair health. Allogeneic HCT recipients were 2.2-fold more likely to report their health as poor or fair, as compared with autologous HCT recipients (OR ¼ 2.15, 95% CI 1.1-4.2, P ¼ 0.03). Survivors with a history of cGvHD were more than twice as likely to report abnormal sense of touch (OR ¼ 2.3, 95% CI 1.2-4.7, P ¼ 0.03), problems with balance, tremor or weakness (OR ¼ 2.6, 95% CI 1.1-6.1, P ¼ 0.02), and they were nearly three times more likely to report that their health prevented school or work attendance (OR ¼ 2.9, 95% CI 1.3-6.4, P ¼ 0.008). Despite these outcomes they were no more likely than survivors without cGvHD to report their health as being poor or fair.
Discussion
This report is the first to describe medical late effects and functional status in a large population of AL patients treated with HCT. We found that HCT survivors are at a significantly higher risk of developing chronic health conditions such as cataracts, oral health issues, hypothyroidism, diabetes, bone health abnormalities, gastrointestinal and neurological impairments, when compared with a healthy comparison group (although the differences in the prevalence of reported outcomes is large for some and small for others). Compared with their siblings, a minority of HCT survivors also reported the need for assistance with activities of daily living, other routine activities, or that their poor health prevented them from working or attending school, which resulted in an overall poor rating of their health. However, despite these medical late effects and functional limitations, over 80% of the HCT survivors rated their overall health as good, very good or excellent. Not surprisingly, recipients of allogeneic transplants and especially those who had cGvHD, were more likely to report adverse health conditions, functional impairments and to rate their overall health as fair or poor. This analysis does not account for the comparative severity of different impairments that survivors face (that is, diabetes may be considered a more severe impairment than dry mouth, for example). However, we have shown that survivors face an overall greater burden of impairments with two-thirds of survivors facing impairments in two or more organ systems.
Overall, primary diagnosis of ALL or AML had little effect on the risk of specific long-term complications, functional or health status after HCT. As management of ALL necessitates use of steroids, one might have expected a higher risk of outcomes such as diabetes, osteoporosis and avascular necrosis, but that was not the case. Our cohort includes individuals who had survived at least 2 years after HCT, and it is possible that events such as avascular necrosis may have occurred earlier post-HCT in patients who died before entering our cohort, and thus were not captured in this study. Furthermore, we were not able to capture steroid exposure after HCT in this study, but we did not find that the risk of these outcomes was increased among patients who had cGvHD (and thus likely steroid exposure) than in those who did not have cGvHD.
We examined the effect of the preparative regimen, particularly TBI exposure, which has been reported to be associated with several long-term complications including hypothyroidism, [14] [15] [16] cataracts, [16] [17] [18] second cancers 7, 8, 19 and diabetes. 20, 21 We found several similar associations in this study, although interestingly did not find a higher risk of hypothyroidism associated with TBI in this cohort. We also did not find that TBI was related to long-term pulmonary complications such as EISB. In fact, this was reported less frequently in patients who had received TBI. Although we do not report the details of the non-TBI-based conditioning regimens, the majority of these patients received busulfan-based regimens. Busulfan is known to have the potential to lead to long-term pulmonary toxicities and pulmonary fibrosis, 22 but the occurrence of fibrosis in HCT recipients independent of cGvHD is uncommon, and typically has not been reported more frequently in busulfan-vs TBI-based preparative regimens. 23, 24 We have previously reported the association of TBI with the development of diabetes, 20 however, in this analysis we were not able to show this association as the number of events was too small to make reliable risk estimates. Diabetes was, however, reported more commonly among survivors than among siblings. This analysis reveals that allogeneic HCT recipients fare worse than the autologous HCT recipients, and have a higher risk of developing dry eyes, diabetes, osteoporosis, avascular necrosis, abnormal sense of touch and poorer overall health. In the analysis restricted to allogeneic HCT recipients the only significant risk factor for several of these outcomes was cGvHD, which also had an effect on the survivors' health status and made them less likely to be able to attend school or work. Autologous HCT recipients are not at risk for cGvHD, and therefore do not carry the risk of adverse events that are typically associated with cGvHD.
In a previous study, we have shown that cGvHD has a significant impact on general health, mental health, functional status, activities of daily living and pain in HCT survivors. 25 In this study, cGvHD remains one of the primary risk factors for the development of chronic health conditions or activity limitations in leukemia survivors after allogeneic HCT. However, allogeneic HCT survivors with a history of cGvHD were not any more likely to report their overall health as fair or poor compared with allogeneic survivors who did not have cGvHD. This finding is similar to what we have reported previously in which only a history of having had cGvHD in itself did not have a negative impact on overall health status if the cGvHD was considered resolved. 25 Although management options for cGvHD have improved, the increasing use of mismatched and unrelated donors, peripheral blood stem-cell grafts and donor lymphocyte infusions have prevented a decline in its incidence, thus aggressive surveillance and multidisciplinary management of secondary complications in patients with cGvHD is critical.
One of the purposes of a disease focused analyses of longterm complications after HCT such as this is to determine whether there are unique aspects of the underlying disease or type of treatment received before HCT that might impact the long-term outcomes after HCT. Although we are not able to account for pretransplant treatment factors in this analysis, there are not significant differences in the types of post-transplant late effects discovered in this analysis as compared with what has been reported for survivors after HCT for chronic myeloid leukemia, 5 or for survivors after HCT for lymphoma. 6 In addition, despite exposure to anthracyclines in the majority of AL patients, we did not find an increased risk of cardiopulmonary impairments overall, or for congestive heart failure in particular, in HCT survivors compared with sibling controls. The subjects in all three of these studies however were mostly adults. It is possible that in a pediatric population there may be a greater impact of pre-HCT treatments on subsequent post-HCT late effects. In addition, differences may begin to appear with longer follow-up of these cohorts.
There are limitations to this study that must be considered when interpreting the findings. The data are collected by selfreport and subject to potential misclassification bias in which subjects may either incorrectly report conditions that they did not have, or fail to report conditions that they did have. However, a validation study of the Bone Marrow Transplant Survivor Study instrument showed very good agreement between self-reported conditions and those abstracted from medical records. 13 In addition, the control group (siblings) also provided self-reported data, thus there should not be any systematic bias based on case or sibling status. Participation rate was 59.6% of those presumed eligible and 69% of those successfully contacted, which could introduce some bias if the prevalence of outcomes among study participants differed significantly from that of nonparticipants. We know that participants did not differ from nonparticipants by time since transplant, treating institution, stem-cell source or myeloablative regimen. However, as is true for most large HCT cohort studies, participants were more likely to be female, to have a diagnosis of AML and to be slightly older than nonparticipants at time of HCT and at time of study participation. Finally, participants in this study had to be alive at least 2 years after HCT to be eligible for study participation, and thus there may be an underestimation for some outcomes that might have occurred in patients who died within the first 2 years after HCT.
A final issue is whether these results are relevant in the current era of HCT as patients in this study received their transplants over 10 years ago. For patients with AL, the most common myeloablative preparative regimens in use (busulfan/cyclophosphamide or TBI/cyclophosphamide) have not changed significantly over the past three decades. In addition, although HLA matching methods have improved, the incidence of cGvHD in this cohort (40-45%) is not significantly different than what is observed currently, thus we feel the data maintain their relevance even in the context of patients receiving HCT currently.
In summary, this study provides disease-specific data on longterm outcomes in a large cohort of survivors after HCT for AL. Many of the impairments that have been identified are potentially amenable to interventions targeted towards either prevention or amelioration of the negative impact on the survivors' overall health and well-being. We have also shown that at one end of the spectrum, one-third of survivors report no long-term impairments, whereas at the other end the other third report having multiple impairments. Therefore, we have identified that there is a subset of survivors for which we should be focusing additional efforts toward support and intervention. The data also indicate that appropriate education of health-care providers regarding issues facing HCT survivors, as well as education of survivors themselves, will be required for maintaining their long-term heath.
